AR068368A1 - Formas solidas de dosificacion de azitromicina de liberacion controlada - Google Patents

Formas solidas de dosificacion de azitromicina de liberacion controlada

Info

Publication number
AR068368A1
AR068368A1 ARP080103847A ARP080103847A AR068368A1 AR 068368 A1 AR068368 A1 AR 068368A1 AR P080103847 A ARP080103847 A AR P080103847A AR P080103847 A ARP080103847 A AR P080103847A AR 068368 A1 AR068368 A1 AR 068368A1
Authority
AR
Argentina
Prior art keywords
solid forms
azithromycin dosage
controlled liberation
azithromycin
pharmaceutical form
Prior art date
Application number
ARP080103847A
Other languages
English (en)
Spanish (es)
Original Assignee
Dow Pharmaceutical Sciences
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dow Pharmaceutical Sciences filed Critical Dow Pharmaceutical Sciences
Publication of AR068368A1 publication Critical patent/AR068368A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/284Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846Poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891Coated capsules; Multilayered drug free capsule shells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/10Anti-acne agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ARP080103847A 2007-09-05 2008-09-04 Formas solidas de dosificacion de azitromicina de liberacion controlada AR068368A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US96750407P 2007-09-05 2007-09-05
US12/002,417 US8124123B2 (en) 2007-09-05 2007-12-17 Controlled release azithromycin solid dosages forms

Publications (1)

Publication Number Publication Date
AR068368A1 true AR068368A1 (es) 2009-11-11

Family

ID=40407900

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080103847A AR068368A1 (es) 2007-09-05 2008-09-04 Formas solidas de dosificacion de azitromicina de liberacion controlada

Country Status (12)

Country Link
US (2) US8124123B2 (OSRAM)
EP (2) EP2197420A4 (OSRAM)
JP (2) JP2010538062A (OSRAM)
KR (2) KR20100063088A (OSRAM)
CN (2) CN101861138A (OSRAM)
AR (1) AR068368A1 (OSRAM)
AU (2) AU2008295579A1 (OSRAM)
BR (1) BRPI0816268A2 (OSRAM)
CA (2) CA2697496A1 (OSRAM)
RU (2) RU2010109358A (OSRAM)
WO (2) WO2009032037A1 (OSRAM)
ZA (2) ZA201001649B (OSRAM)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101797221B (zh) 2002-12-13 2013-06-12 杜雷科特公司 包含高粘度液体载体材料的口服递药系统
WO2009075782A1 (en) 2007-12-06 2009-06-18 Durect Corporation Methods useful for the treatment of pain, arthritic conditions, or inflammation associated with a chronic condition
US20100260844A1 (en) 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
TW201521769A (zh) 2013-03-15 2015-06-16 Durect Corp 具有流變改質劑以減少溶解變異性之組成物
MY205229A (en) 2016-07-06 2024-10-08 Durect Corp Oral dosage form with drug composition, barrier layer and drug layer
NZ752894A (en) * 2016-10-06 2023-05-26 Orbus Therapeutics Inc Formulations for administration of eflornithine
CN109875970B (zh) * 2019-01-08 2021-08-06 石家庄四药有限公司 阿奇霉素固体制剂及其制备方法
CN113116859B (zh) * 2021-04-12 2022-08-30 海南普利制药股份有限公司 阿奇霉素丸芯包衣制剂
WO2023283427A2 (en) * 2021-07-09 2023-01-12 Verdure Biotech, Inc. Enteric and delayed release formulations of locally bioavailable drugs (lbd) targeting the colon

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4474768A (en) * 1982-07-19 1984-10-02 Pfizer Inc. N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor
US5605889A (en) * 1994-04-29 1997-02-25 Pfizer Inc. Method of administering azithromycin
NZ283160A (en) * 1994-05-06 1998-07-28 Pfizer Azithromycin in a controlled release dosage form for treating microbiol infections
US5543417A (en) * 1994-10-21 1996-08-06 Merck & Co., Inc. Combination method of treating acne using 4-AZA-5α-cholestan-ones and 4-AZA-5α-androstan-ones as selective 5α-reductase inhibitors with anti-bacterial, keratolytic, or anti-inflammatory agents
WO1998029095A2 (en) * 1997-01-03 1998-07-09 Elan Corporation, Plc Sustained release cisapride mini-tablet formulation
US6368628B1 (en) * 2000-05-26 2002-04-09 Pharma Pass Llc Sustained release pharmaceutical composition free of food effect
US7670627B2 (en) * 2002-12-09 2010-03-02 Salvona Ip Llc pH triggered targeted controlled release systems for the delivery of pharmaceutical active ingredients
PL1663216T3 (pl) * 2003-08-29 2012-03-30 Veloxis Pharmaceuticals As Kompozycje o zmodyfikowanym uwalnianiu zawierające takrolimus
US20050239723A1 (en) * 2004-04-27 2005-10-27 Amin Avinash N Compositions and methods useful for treatment of acne
US20080199527A1 (en) 2004-12-21 2008-08-21 Pfizer Inc. Enteric Coated Azithromycin Multiparticulates
US20060280789A1 (en) * 2004-12-27 2006-12-14 Eisai Research Institute Sustained release formulations
CN101217944A (zh) * 2005-04-08 2008-07-09 艾博特公司 包含非诺贝酸和/或其盐的口服药物制剂
US20070105788A1 (en) * 2005-11-09 2007-05-10 Serena Mraz-Gernhard Azithromycin for treatment of granulomatous rosacea
US7704959B2 (en) * 2006-10-03 2010-04-27 Dow Pharmaceutical Sciences Azithromycin for the treatment of nodular acne

Also Published As

Publication number Publication date
CA2697496A1 (en) 2009-03-12
ZA201001705B (en) 2010-12-29
RU2010109359A (ru) 2011-10-20
KR20100054842A (ko) 2010-05-25
RU2010109358A (ru) 2011-10-20
JP2010538066A (ja) 2010-12-09
AU2008295579A1 (en) 2009-03-12
CA2697537A1 (en) 2009-03-12
CN101861138A (zh) 2010-10-13
US20090060994A1 (en) 2009-03-05
BRPI0816268A2 (pt) 2017-08-22
ZA201001649B (en) 2010-11-24
WO2009032037A1 (en) 2009-03-12
KR20100063088A (ko) 2010-06-10
US20120121702A1 (en) 2012-05-17
EP2197420A1 (en) 2010-06-23
EP2197453A1 (en) 2010-06-23
WO2009032268A1 (en) 2009-03-12
US8124123B2 (en) 2012-02-28
JP2010538062A (ja) 2010-12-09
CN101835475A (zh) 2010-09-15
AU2008296903A1 (en) 2009-03-12
EP2197420A4 (en) 2010-10-20
EP2197453A4 (en) 2010-10-20

Similar Documents

Publication Publication Date Title
AR068368A1 (es) Formas solidas de dosificacion de azitromicina de liberacion controlada
CR20140340A (es) Formas farmacéuticas de dosificación oral resistente a interferencias que comprenden un analgésico opioide
CR11740A (es) Composiciones que comprenden fármacos levemente básicos y formas de dosificación de liberación controlada
BRPI1012831A2 (pt) forma de dosagem farmacêutica para administração oral de um inibidor da família bcl-2.
BRPI0906467A2 (pt) forma de dose farmacêutica
BRPI0814666A2 (pt) composição farmacêutica para a administração oral, uso de uma formulação. processo para a preparação de uma forma de dosagem sólida, e, forma de dosagem sólida
CR11709A (es) Preparacion solida de desintegracion oral
BRPI0818680A2 (pt) composição farmacêutica, preparação farmacêutica, e método para preparar um forma de dosagem oral farmacêutica
DK2077729T3 (da) Orale probiotiske doseringsformer
CL2012000626A1 (es) Composición farmacéutica oral de liberación sostenida, que comprende dentro de una forma de dosificación única, (i) una matriz hidrofílica, (ii) una cantidad terapéuticamente eficaz de un compuesto no opioide que contiene amina, (iii) una sal de un fármaco aine, y (iv) opcionalmente un surfactante aniónico.
GT200900096A (es) Formas de dosificación de clorhidrato de palonosetron que tienen estabilidad y biodisponibilidad mejorada
CR20110110A (es) Composicion farmaceutica
BR112012003280A2 (pt) composição farmacêutica para administração oral, método para tratar uma doença, uso do composto, e, composto.
BR112013009153A2 (pt) formulação de ligante de fosfato para dosagem única.
CL2014001828A1 (es) Sistema de dosificacion oral de liberacion dual que comprende doxilamina y piridoxina y/o sus analogos, metabolitos y sales de los mismos; forma de dosificacion oral de liberacion dual; kit farmaceutico; uso para aliviar los sintomas de nauseas y vomitos, incluidos los del embarazo.
CR20140334A (es) Forma galénica divisible que permite una liberación modificada del principio activo
BRPI0913235A2 (pt) forma de dosagem farmacêutica para liberação imediata de um derivado de indolinona
BRPI0719880A2 (pt) Forma de dosagem sólida farmacêutica para administração oral e método para preparar a mesma.
ECSP11011289A (es) Formulaciones galénicas de compuestos orgánicos
CR11744A (es) Formulacion liquida para deferiprona con gusto agradable al paladar
CO6801754A2 (es) Una composición farmacéutica para tratar una enfermedad en la cavidad oral que comprende rebamipida
BRPI0922806A2 (pt) formas de dosagem oral de bendamustina
BRPI1007484A2 (pt) composição farmacêutica para administração oral
BRPI0918539A2 (pt) preparação farmacêutica sólida para administração oral
BRPI0909211B8 (pt) formulação oral em forma de comprimido de compostos de tetraciclina

Legal Events

Date Code Title Description
FA Abandonment or withdrawal